STTR Phase II: VaxMAP a single dose multivalent vaccine to produce durable and cross-react — NSF Award to Tempo Therapeutics (CA,
The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project will address the unmet need for more effective vaccines that can be rapidly deployed to decrease the lag time between pathogen emergence and vaccine development, minimizing socioeconomic effects such as those seen
| Award title | STTR Phase II: VaxMAP a single dose multivalent vaccine to produce durable and cross-react |
|---|---|
| Award ID | 2308751 |
| Awardee | Tempo Therapeutics |
| City | SAN DIEGO |
| State | CA |
| Amount obligated | $1,000,000 |
| Principal investigator | Stephanie Deshayes |
| Program | STTR Phase II |
| Start date | 06/15/2023 |
| Abstract | The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project will address the unmet need for more effective vaccines that can be rapidly deployed to decrease the lag time between pathogen emergence and vaccine development, minimizing socioeconomic effects such as those seen in the COVID-19 pandemic. This new vaccine technology has the potential to drastically improve the lives of US citizens during future outbreaks of new pathogens. Further, this new |
| Source | NSF Awards |
$799/mo
Try NSFGrants →